EMA’s Cancer ‘Pathfinder’ Project Targets Conditional Approvals, Endpoints & RWE
This second of a two-part article on the EU’s “Cancer Medicines Pathfinder” initiative looks at the trade-off between the benefits and risks of conditional drug approvals and differing perceptions of progression-free survival as a validated endpoint in cancer drug trials.
You may also be interested in...
The Pathfinder initiative is intended to accelerate cancer drug development and assessment, strengthen international collaboration, and improve the way the EMA communicates about the benefits and risks of cancer medicines.
The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.
New EU guidance will cover non-clinical and clinical development, trial design, endpoints, safety issues and comparators, as well as the use of immunobridging studies.